Transcranial magnetic stimulation in mental health care.

Background: Transcranial magnetic stimulation (TMS), which is a neuromodulation therapy for psychiatric disorders, is not widely used in Norway. We aimed to investigate whether doctors in mental health care are familiar with and interested in the method, as well as the reasons for its limited use and the key factors required for its implementation.

Material And Method: An anonymous electronic survey questionnaire was distributed to all active members of the Norwegian Psychiatric Association in the autumn of 2022 (n = 1979), consisting of 484 specialty registrars and 1495 specialists.

Frequency and patterns of substance-induced psychosis in persons with concurrent mental health and substance use disorders during the COVID-19 pandemic: A Norwegian register-based cohort study.

Background: Substance use may be associated with the onset of psychotic symptoms, necessitating treatment for individuals with comorbid mental health and substance use disorders (MHD/SUD). COVID-19 significantly impacted individuals with MHD/SUD, reducing access to appropriate care and treatment. Changes in drug availability and prices during the pandemic may have influenced drug consumption.

Effect of a Reduced PCV10 Dose Schedule on Pneumococcal Carriage in Vietnam.

Background: After pneumococcal disease and colonization have been controlled through vaccination campaigns, a reduced pneumococcal conjugate vaccine (PCV) schedule may be sufficient to sustain that control at reduced costs.

Methods: We investigated whether a single primary dose and booster dose (1p+1) of the 10-valent PCV (PCV10) would be noninferior to alternative dose schedules in sustaining control of carriage of pneumococcal serotypes included in the vaccine. In Nha Trang, Vietnam, an area in which PCV had not been used previously, a PCV10 catch-up campaign was conducted in which the vaccine was offered to children younger than 3 years of age, after which a cluster-randomized trial was conducted in which children received PCV10 at 2, 3, and 4 months of age (3p+0 group); at 2, 4, and 12 months of age (2p+1 group); at 2 and 12 months of age (1p+1 group); or at 12 months of age (0p+1 group).